checkAd

     321  0 Kommentare Trillium Therapeutics Joins Russell 2000 and 3000 Indices - Seite 3

    Company Contact:
    Rosemary Harrison
    SVP, Corporate Development and Strategy
    Trillium Therapeutics Inc.
    857-412-7029 x225
    investors@trilliumtherapeutics.com
    www.trilliumtherapeutics.com  

    Lesen Sie auch

    Media Relations:
    Mike Beyer
    Sam Brown Inc.
    312-961-2502
    mikebeyer@sambrown.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3
    Verfasst von globenewswire
    Trillium Therapeutics Joins Russell 2000 and 3000 Indices - Seite 3 CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) - Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, joins the …